Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease
Year: 2026
Type: article
Source: New England Journal of Medicine
Authors: Paul M Ridker, A. Michael Lincoff, Nikolaus Marx, Ann Marie Navar, Naveed Sattar, Katherine R. Tuttle, Matthew Budoff, Morten Böttcher, Matthew A. Cavender, Robin P. Choudhury, Jan H. Cornel, Grzegorz Gajos, Issei Komuro, K.M.K. Reddy Parvathareddy, Roberto Pontremoli, José Francisco Kerr Saraiva, Iana I. Simova, Lance A. Sloan, Alejandro López-Suárez, Yi-Da Tang, Lale Tokgözoğlu, Nqoba Tsabedze, Konstantinos Tsioufis, Subodh Verma, Mathias Vrolix, Andreas Andersen, Florian M.M. Baeres, Kathrine Ekström, Mads D.M. Engelmann, Sofia Gerward, G. Kees Hovingh, Anders Hvelplund, Vlado Perkovic
Institutions: Massachusetts General Hospital, Mass General Brigham, Cleveland Clinic, Universitätsklinikum Aachen, RWTH Aachen University, The University of Texas Southwestern Medical Center, University of Glasgow, Inland Northwest Health Services, University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center, Aarhus University, University of North Carolina at Chapel Hill, University of Oxford, Radboud University Medical Center, Noordwest Ziekenhuisgroep, Jagiellonian University, International University of Health and Welfare, Osmania General Hospital, IRCCS Azienda Ospedaliera Metropolitana, University of Genoa, Universidade Estadual de Campinas (UNICAMP), Medical University Pleven, Peking University Third Hospital, Hacettepe University, University of the Witwatersrand, Johannesburg Hospital, National and Kapodistrian University of Athens, Hippocration General Hospital, St. Michael's Hospital, Unity Health Toronto, Ziekenhuis Oost-Limburg, Novo Nordisk (Denmark)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7225465743